Trimph Industries

Trimph Industries is a biomedical company that has developed a platform technology to repair bone, cartilage and connective tissues.

Trimph Industries is a biomedical company that has developed a platform technology to repair bone, cartilage and connective tissues. The properties of this material can be tuned to treat a number of pathologies including osteoarthritis, bone defects and maxillofacial disorders. The technology was developed by Trimph’s co-founder, Dr Ali Fathi at the University of Sydney. Since Trimph’s incorporation in August 2015, the company has established its own ISO 13485 accredited production facility, received granted patents in the US and Europe and progressed to clinical trials. Trimph’s Sydney based, ISO13485 compliant production facility provides the infrastructure to produce material for multiple clinical trials and is capable of servicing the Australian market. Trimph aims to use the data generated through clinical studies to transition the technology into high growth sectors. This model mitigates risk to the company and potential investors prior to embarking on a costly clinical development and facilitates a dynamic transition to high growth sectors.